A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Phase of Trial: Phase II
Latest Information Update: 23 May 2013
At a glance
- Drugs Sunitinib (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Pfizer
- 19 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 24 Jun 2010 Planned end date changed from 1 Jul 2012 to 1 Aug 2012 as reported by ClinicalTrials.gov.
- 12 Apr 2007 New trial record.